Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Ring closure from a sulfonate
What ifWhat if a saturated precursor with a terminal sulfonate forms the cyclopropane bridge by intramolecular alkylation?
Claim language“cyclopropanating a compound represented by formula (II)”
The saturated precursor contains a tether that places a primary sulfonate two carbon atoms away from a carbon bearing an ester. Base generates the ester enolate, which displaces the sulfonate and closes the three-membered ring.
1.1Cyano substitution on the base
What ifWhat if the nucleic acid base carries a cyano group at the 5-position of a uracil ring?
Claim language“an alkyl group of 1 to 5 carbon atoms”
A glycosylation step attaches 5-cyanouracil to the sugar precursor through the N1 atom. A methylene-transfer reagent then reacts with the protected precursor at its sugar alkene to form the cyclopropane bridge while retaining the base nitrile.
1.2Shared cyclic carbonate protection
What ifWhat if a single cyclic carbonate links the two hydroxyl oxygens during bridge formation?
Claim language“R1 and R2 each independently represent”
A suitably oriented diol reacts with a carbonyl transfer reagent to form a cyclic carbonate with one carbonyl carbon shared by both oxygens. Hydrolysis after bridge formation opens the carbonate and regenerates both hydroxyl groups.
1.3Direct phenyl attachment
What ifWhat if a phenyl ring attaches directly at R5 in place of an alkyl group?
Claim language“an optionally branched or cyclic alkyl group”
The alkene precursor carries a direct bond between an alkene carbon and a phenyl carbon. Methylene transfer converts the alkene into a cyclopropane and retains the direct bond between the phenyl group and the resulting ring carbon.
1.3Nitrile on the bridge carbon
What ifWhat if a cyano group occupies R5 in place of a halogen atom?
Claim language“a halogen atom”
The precursor carries the cyano group directly on the alkene carbon that becomes the substituted cyclopropane carbon. A sulfonium methylide adds to the nitrile-activated double bond, and the resulting intermediate closes to the cyclopropane with loss of a sulfide.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Bridged nucleoside standards for analytical laboratories
An analytical laboratory cyclopropanates a protected nucleoside precursor and treats the reaction mixture with ammonia. Preparative liquid chromatography separates the bridged product from residual precursor and side products. Mass spectrometry and nuclear magnetic resonance spectroscopy establish the identity of the isolated material, which the laboratory uses to assign peaks in chromatograms of bridged nucleoside mixtures.
Component substitution
Citrate workup for zinc removal
A zinc-mediated cyclopropanation uses an aqueous sodium citrate wash in place of the ammonia post-treatment. A separate controlled quench consumes residual organozinc reagent before the citrate solution contacts the mixture. Citrate binds zinc in the aqueous phase, and the product-bearing organic phase proceeds to a water wash and solvent removal.
Parameter or scale variation
Parallel reactions on a millimole scale
Four independently stirred 100 mL vessels each receive 1.0 mmol of the same alkene precursor in 20 mL of reaction solvent. Each vessel receives the same reagent charge per mole of precursor and undergoes separate ammonia post-treatment. Liquid chromatography measures residual precursor and product in each vessel, and batches that meet the same acceptance criteria are pooled for purification.
Combination with existing systems
Inline liquid extraction after ammonia treatment
The ammonia-treated mixture feeds a liquid-liquid extraction train with a mixing stage followed by a gravity settler. A pump meters a water-immiscible extraction solvent into the mixer, and the settler drains the aqueous and organic phases through separate outlets. A second mixer and settler wash the product-bearing organic stream with water before solvent removal.
Fraction collection by preparative liquid chromatography
A preparative reversed-phase liquid chromatograph receives the concentrated extract from the ammonia post-treatment after the extract is redissolved in the starting mobile phase. A water and acetonitrile gradient separates the bridged nucleoside from residual precursor and other organic components. A fraction collector routes the product peak to separate vessels, and analytical chromatography verifies which fractions to pool for solvent removal.
An automated sampler withdraws timed aliquots from the stirred cyclopropanation vessel into vials containing a quench solution and an internal standard. Liquid chromatography measures the precursor concentration using a stored calibration curve. The controller initiates ammonia post-treatment after two consecutive measurements place the residual precursor below a preset threshold.
Specific version of a part
Thymine as the base
The sugar precursor carries thymine through a bond to its N1 atom. The methyl group occupies C5 of the pyrimidine ring and remains attached during cyclopropanation of the sugar alkene.
Acetyl and benzoyl protection
One hydroxyl oxygen carries an acetyl group and the other carries a benzoyl group. The two ester groups mask the hydroxyls during cyclopropanation, and subsequent ester cleavage regenerates the diol.
Methyl on the bridge carbon
The alkene precursor carries a methyl group on the carbon corresponding to R5. Methylene transfer forms the three-membered ring and retains the methyl group on that carbon.
Aqueous ammonia zinc workup
After cyclopropanation and quenching of residual organozinc reagent, the mixture receives aqueous ammonia. Excess ammonia binds zinc ions, and phase separation removes the zinc-containing aqueous fraction from the organic product solution.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1X, R1, R2 and R5 are as defined below, and R5′ is independently as defined for R5, the method comprising cyclopropanating a compound represented by formula (II): wherein X represents a nucleic acid base moiety optionally having one or more substituents selected from a group α consisting of a hydroxy group, a hydroxy group protected by a protecting group for nucleic acid synthesis, an alkyl group of 1 to 5 carbon atoms, an alkoxy group of 1 to 5 carbon atoms, a mercapto group, a mercapto group protected by a protecting group for nucleic acid synthesis, an alkylthio group of 1 to 5 carbon atoms, an amino group, an amino group protected by a protecting group for nucleic acid synthesis, an amino group substituted with an alkyl group of 1 to 5 carbon atoms, and a halogen atom
1.2R1 and R2 each independently represent a hydrogen atom, a protecting group for a hydroxy group used in nucleic acid synthesis, an optionally branched or cyclic alkyl group of 1 to 7 carbon atoms, an optionally branched or cyclic alkenyl group of 2 to 7 carbon atoms, an aryl group of 3 to 10 carbon atoms optionally having one or more substituents selected from the group α and optionally containing a heteroatom, an aralkyl group having an aryl moiety of 3 to 12 carbon atoms optionally having one or more substituents selected from the group α and optionally containing a heteroatom, an acyl group optionally having one or more substituents selected from the group α, a silyl group optionally having one or more substituents selected from the group α, a phosphate group optionally having one or more substituents selected from the group α, a phosphate group protected by a protecting group for nucleic acid synthesis, or —P(R3)R4 (wherein R3 and R4 each independently represent a hydroxy group, a hydroxy group protected by a protecting group for nucleic acid synthesis, a mercapto group, a mercapto group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group of 1 to 5 carbon atoms, an alkylthio group of 1 to 5 carbon atoms, a cyanoalkoxy group of 1 to 6 carbon atoms, or an amino group substituted with an alkyl group of 1 to 6 carbon atoms)
Any suitable protecting groups can be utilized to protect the terminal group of the incoming monomer or dimer nucleoside reactant during coupling. In certain instances, the terminal group is a hydroxyl, an amino or a thiol group and the protecting group is an acid-labile protecting group such as a triarylmethyl protecting group (e.g., DMT (4,4′-dimethoxytriphenylmethyl)) or a BOC carbamate (tert-butoxycarbonyl), or a base-labile protecting group, such as a FMOC (fluorenylmethyloxycarbonyl).
A · US 10,072,261 B1 · ¶ 56
1.3R5 represents a hydrogen atom, a halogen atom, an optionally branched or cyclic alkyl group of 1 to 7 carbon atoms optionally substituted with an aryl group of 3 to 12 carbon atoms optionally containing a heteroatom, an aralkyl group having an aryl moiety of 3 to 12 carbon atoms optionally containing a heteroatom, or a silyl group
The reaction mixture of claim 1, wherein the cyclopropanation product is a compound according to Formula I: wherein: R1 is independently selected from the group consisting of H, optionally substituted C1-18 alkyl, optionally substituted C6-10 aryl, optionally substituted 6- to 10-membered heteroaryl, halo, cyano, C(O)OR1a, C(O)N(R7)2, C(O)R8, C(O)C(O)OR8, and Si(R8)3;
B · US 10,208,322 B2 · claim 2
1.4wherein the cyclopropanation comprises post-treatment of a reaction mixture with ammonia.
An empty cell means only that no passage was reproduced there.
Statements in these documents
The method finds use in synthesizing an oligonucleotide on a solid phase support, such as a planar support surface that finds use in oligonucleotide arrays.
A · US 10,072,261 B1 · ¶ 4
The double coupling method can be utilized at one or more nucleotide positions during oligonucleotide synthesis thereby reducing single base deletion rates.
A · US 10,072,261 B1 · ¶ 4
As such, there is a need in the art for novel reagents and catalytic schemes that are capable of creating the cyclopropane motif with high yield, regioselectivity, and stereoselectivity, but without the toxicity and harsh reaction conditions associated with current approaches.
B · US 10,208,322 B2 · ¶ 5
The present invention satisfies this need by providing novel iron-heme-containing enzyme catalysts for producing cyclopropanation products in vitro and in vivo, and offers related advantages as well.
B · US 10,208,322 B2 · ¶ 5
Cite aspatent.fyi, US 2026/0356875 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356875/, SHA-256 8e4ac38d2ced8a1edd9d64a8da0bf4b33909cce5f693b4afcb220231e3c2a3f1